Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advi...
GSK plc (LSE/NYSE: GSK) today announced that it intends to sell approximately 385m ordinary shares in Haleon, equivalent to app...
https://www.haleon.com/news/press-releases/corporate/2024/appointment-of-dawn-allen-as-chief-financial-officer
Argus Research analyst Taylor Conrad maintains Haleon (NYSE:HLN) with a Buy and maintains $10 price target.
Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be re...
Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit r...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...
